Unity Biotechnology Stock Price To Book

UBX Stock

USD 1.21 0.02 1.68%

Unity Biotechnology fundamentals help investors to digest information that contributes to Unity Biotechnology's financial success or failures. It also enables traders to predict the movement of Unity Stock. The fundamental analysis module provides a way to measure Unity Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Unity Biotechnology stock.

Other Current Liab Total Assets

Price To Book Ratio is likely to rise to 1.07 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Unity Biotechnology Company Price To Book Analysis

Unity Biotechnology's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

P/B

MV Per Share

BV Per Share

More About Price To Book | All Equity Analysis

Current Unity Biotechnology Price To Book

1.36 X

Most of Unity Biotechnology's fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Unity Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Unity Price To Book Driver Correlations

Understanding the fundamental principles of building solid financial models for Unity Biotechnology is extremely important. It helps to project a fair market value of Unity Stock properly, considering its historical fundamentals such as Price To Book. Since Unity Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Unity Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Unity Biotechnology's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Capital Surpluse	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Net Receivables	Long Term Debt Total	Net Invested Capital	Net Working Capital	Deferred Long Term Liab	Capital Stock	Current Deferred Revenue	Short Term Debt	Long Term Debt	Short Long Term Debt
Total Assets		0.78	0.7	0.42	-0.17	0.83	0.29	-0.46	0.86	0.65	0.48	-0.88	0.43	0.77	0.83	0.22	0.35	0.4	0.13	0.25	-0.3
Total Stockholder Equity	0.78		0.78	0.75	-0.52	0.9	0.59	-0.91	0.55	0.76	0.53	-0.78	0.55	0.4	0.54	0.5	0.07	0.25	0.3	-0.18	0.13
Net Tangible Assets	0.7	0.78		0.67	-0.7	0.77	0.81	-0.67	0.46	0.67	0.55	-0.78	0.67	0.22	0.43	0.68	-0.04	0.27	0.42	-0.39	0.34
Net Debt	0.42	0.75	0.67		-0.88	0.45	0.86	-0.81	-0.01	0.67	0.74	-0.65	0.67	-0.16	-0.05	0.79	-0.18	0.47	0.76	-0.62	0.52
Retained Earnings	-0.17	-0.52	-0.7	-0.88		-0.29	-0.98	0.66	0.23	-0.53	-0.65	0.5	-0.7	0.45	0.28	-0.9	0.34	-0.28	-0.83	0.85	-0.75
Accounts Payable	0.83	0.9	0.77	0.45	-0.29		0.42	-0.74	0.73	0.72	0.39	-0.72	0.52	0.55	0.73	0.33	0.23	0.12	0.01	0.08	-0.09
Capital Surpluse	0.29	0.59	0.81	0.86	-0.98	0.42		-0.7	-0.07	0.62	0.67	-0.57	0.71	-0.34	-0.12	0.87	-0.25	0.26	0.76	-0.78	0.67
Total Liab	-0.46	-0.91	-0.67	-0.81	0.66	-0.74	-0.7		-0.22	-0.69	-0.46	0.53	-0.51	-0.01	-0.23	-0.57	0.13	-0.1	-0.37	0.44	-0.39
Total Current Assets	0.86	0.55	0.46	-0.01	0.23	0.73	-0.07	-0.22		0.33	0.02	-0.6	0.0	0.9	0.99	-0.22	0.32	0.01	-0.22	0.48	-0.48
Common Stock	0.65	0.76	0.67	0.67	-0.53	0.72	0.62	-0.69	0.33		0.86	-0.72	0.68	0.18	0.31	0.58	0.54	0.4	0.26	-0.06	-0.12
Property Plant Equipment	0.48	0.53	0.55	0.74	-0.65	0.39	0.67	-0.46	0.02	0.86		-0.67	0.8	-0.04	-0.02	0.73	0.42	0.7	0.5	-0.2	0.02
Net Receivables	-0.88	-0.78	-0.78	-0.65	0.5	-0.72	-0.57	0.53	-0.6	-0.72	-0.67		-0.64	-0.5	-0.53	-0.57	-0.22	-0.39	-0.52	0.11	0.01
Long Term Debt Total	0.43	0.55	0.67	0.67	-0.7	0.52	0.71	-0.51	0.0	0.68	0.8	-0.64		-0.07	-0.05	0.89	0.11	0.6	0.46	-0.33	0.28
Net Invested Capital	0.77	0.4	0.22	-0.16	0.45	0.55	-0.34	-0.01	0.9	0.18	-0.04	-0.5	-0.07		0.89	-0.31	0.42	0.11	-0.35	0.67	-0.63
Net Working Capital	0.83	0.54	0.43	-0.05	0.28	0.73	-0.12	-0.23	0.99	0.31	-0.02	-0.53	-0.05	0.89		-0.28	0.33	-0.01	-0.3	0.52	-0.5
Deferred Long Term Liab	0.22	0.5	0.68	0.79	-0.9	0.33	0.87	-0.57	-0.22	0.58	0.73	-0.57	0.89	-0.31	-0.28		-0.14	0.39	0.71	-0.68	0.6
Capital Stock	0.35	0.07	-0.04	-0.18	0.34	0.23	-0.25	0.13	0.32	0.54	0.42	-0.22	0.11	0.42	0.33	-0.14		0.24	-0.42	0.69	-0.84
Current Deferred Revenue	0.4	0.25	0.27	0.47	-0.28	0.12	0.26	-0.1	0.01	0.4	0.7	-0.39	0.6	0.11	-0.01	0.39	0.24		0.22	0.09	-0.08
Short Term Debt	0.13	0.3	0.42	0.76	-0.83	0.01	0.76	-0.37	-0.22	0.26	0.5	-0.52	0.46	-0.35	-0.3	0.71	-0.42	0.22		-0.79	0.64
Long Term Debt	0.25	-0.18	-0.39	-0.62	0.85	0.08	-0.78	0.44	0.48	-0.06	-0.2	0.11	-0.33	0.67	0.52	-0.68	0.69	0.09	-0.79		-0.95
Short Long Term Debt	-0.3	0.13	0.34	0.52	-0.75	-0.09	0.67	-0.39	-0.48	-0.12	0.02	0.01	0.28	-0.63	-0.5	0.6	-0.84	-0.08	0.64	-0.95

Click cells to compare fundamentals

Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

Competition

Predict Unity Biotechnology

Price Book Value Ratio Over Time

Unity Book Value Per Share

Book Value Per Share

1.83

At this time, Unity Biotechnology's Book Value Per Share is fairly stable compared to the past year.

Based on the latest financial disclosure, Unity Biotechnology has a Price To Book of 1.3581 times. This is 94.71% lower than that of the Biotechnology sector and 77.51% lower than that of the Health Care industry. The price to book for all United States stocks is 85.72% higher than that of the company.

Unity Price To Book Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Unity Biotechnology's direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Unity Biotechnology could also be used in its relative valuation, which is a method of valuing Unity Biotechnology by comparing valuation metrics of similar companies.

Unity Biotechnology is currently under evaluation in price to book category among its peers.

Unity Fundamentals

	Return On Equity	-0.87
	Return On Asset	-0.3
	Current Valuation	11.71 M
	Shares Outstanding	16.85 M
	Shares Owned By Insiders	1.30 %
	Shares Owned By Institutions	20.54 %
	Number Of Shares Shorted	303.04 K
	Price To Book	1.36 X
	Price To Sales	6.54 X
	Gross Profit	(35.22 M)
	EBITDA	(37.28 M)
	Net Income	(39.86 M)
	Cash And Equivalents	64.51 M
	Cash Per Share	9.26 X
	Total Debt	26.99 M
	Debt To Equity	1.30 %
	Current Ratio	4.13 X
	Book Value Per Share	0.84 X
	Cash Flow From Operations	(37.09 M)
	Short Ratio	7.70 X
	Earnings Per Share	(1.28) X
	Target Price	7.0
	Number Of Employees	19
	Beta	0.83
	Market Capitalization	20.05 M
	Total Asset	65.69 M
	Retained Earnings	(484.35 M)
	Working Capital	38.77 M
	Net Asset	65.69 M

About Unity Biotechnology Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Unity Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Unity Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Unity Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Unity Stock Analysis

When running Unity Biotechnology's price analysis, check to measure Unity Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unity Biotechnology is operating at the current time. Most of Unity Biotechnology's value examination focuses on studying past and present price action to predict the probability of Unity Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unity Biotechnology's price. Additionally, you may evaluate how the addition of Unity Biotechnology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC